Vtama in Psoriasis Patients Being Treated With Biologics.
Status:
Completed
Trial end date:
2023-10-18
Target enrollment:
Participant gender:
Summary
Open label study to assess 12 weeks of add-on VTAMA® (tapinarof) Cream, 1% QD in patients
with ≥3% BSA who have received biologic therapy for at least 24 weeks.